EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.55 per share a year ago. These figures are adjusted for non- recurring items. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.41 per share when it actually produced a loss of$0.64, delivering a surprise of -56.10%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates ...